Skip to main content

Table 2 Association of HIF-1α, c-Met, CA9 and GLUT1 IHC expression with clinicopathological characteristics in cervical cancer

From: Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry

 

HIF-1α

c-Met

CA9

GLUT1

N

Mean score (95% CI)

p value

N

Mean score (95% CI)

p value

N

Mean score (95% CI)

p value

N

Mean score (95% CI)

p value

Diagnostic category

 

< 0.001

  

< 0.001

  

< 0.001

  

< 0.001

Normal a

313

4.4 (4.0-4.7)

 

346

0.4 (0.3-0.6)

 

314

0.0 (0.0-0.0)

 

357

0.9 (0.7-1.1)

 

Low grade CIN b

54

5.1 (4.3-5.9)

 

62

0.6 (0.2-1.0)

 

55

0.4 (0.0-0.8)

 

40

1.8 (0.9-2.7)

 

High grade CIN b

104

5.4 (4.9-6.0)

 

115

0.7 (0.4-0.9)

 

132

1.9 (1.3-2.5)

 

121

2.2 (1.8-2.7)

 

CIS b

56

5.7 (4.9-6.4)

 

60

1.7 (1.0-2.4)

 

69

1.3 (0.6-1.9)

 

73

2.4 (1.7-3.6)

 

Cervical cancer b

151

5.4 (4.9-6.0)

 

152

4.7 (4.0-5.3)

 

144

2.1 (1.5-2.8)

 

162

4.0 (3.3-4.6)

 

FIGO stage

  

< 0.001

  

0.019

  

0.149

 

0.243

I

96

4.6 (4.0-5.2)

 

98

4.2 (3.4-5.0)

 

95

1.7 (0.9-2.4)

 

114

4.3 (3.5-5.1)

 

II

50

6.9 (5.9-7.9)

 

49

5.2 (3.9-6.4)

 

45

2.9 (1.6-4.1)

 

43

3.1 (2.1-4.0)

 

IV

5

6.0 (2.4-9.5)

 

5

9.2 (3.7-14.6)

 

4

4.0 (−5.0-13.0)

 

5

4.0 (0.4-7.5)

 

Tumor differentiation

 

0.350

  

0.195

  

0.298

 

0.169

Well+Moderate

105

5.6 (4.9-6.2)

 

107

4.4 (3.7-5.2)

 

105

2.4 (1.6-3.1)

 

115

4.1 (3.3-4.8)

 

Poor

40

5.0 (3.9-6.1)

 

40

5.4 (4.0-6.9)

 

37

1.5 (0.3-2.6)

 

41

3.1 (1.8-4.3)

 

Cell Type

  

0.010

  

0.325

  

0.040

 

0.001

SCC

119

5.8 (5.2-6.4)

 

118

4.5 (3.7-5.2)

 

111

1.6 (1.0-2.3)

 

130

4.4 (3.7-5.2)

 

Other

32

4.1 (2.8-5.4)

 

33

5.3 (3.7-6.9)

 

33

3.7 (1.8-5.5)

 

31

1.9 (0.9-2.8)

 

Tumor size

  

0.210

  

0.195

  

0.851

 

0.947

< 4cm

104

5.2 (4.6-5.8)

 

106

4.9 (4.1-5.7)

 

100

2.2 (1.4-2.9)

 

119

4.0 (3.2-4.8)

 

≥ 4cm

47

5.9 (4.9-7.0)

 

46

4.1 (2.9-5.3)

 

44

2.0 (0.9-3.1)

 

43

3.9 (2.8-5.0)

 

LVSI

  

0.725

  

0.001

  

0.998

 

0.801

Negative

73

5.0 (4.2-5.7)

 

74

3.6 (2.7-4.4)

 

65

2.0 (1.0-3.0)

 

84

4.0 (3.1-4.9)

 

Positive

62

5.1 (4.3-6.0)

 

62

5.9 (4.8-7.0)

 

63

2.0 (1.0-3.0)

 

63

4.3 (3.2-5.3)

 

LN metastasis

  

< 0.001

  

0.010

  

0.820

 

0.001

Negative

100

4.4 (3.9-5.0)

 

102

4.0 (3.3-4.8)

 

95

2.0 (1.2-2.8)

 

113

4.5 (3.7-5.4)

 

Positive

37

6.7 (5.5-7.9)

 

36

6.3 (4.8-7.9)

 

35

2.2 (0.8-3.6)

 

36

2.6 (1.6-3.6)

 
  1. Some data of tumor differentiation, LVSI and LN metastasis are not available on retrospective chart review. SCC, squamous cell carcinoma; LVSI, lymphovascular space invasion; a normal sample was constructed with nonadjacent normal epithelium from tumor in same patient, bIHC staining of each marker was evaluated with available tumor cores from 209 CIN, 74 CIS and 179 cancer cores.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us